{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:39:37Z","timestamp":1771234777388,"version":"3.50.1"},"reference-count":27,"publisher":"Academy of Managed Care Pharmacy","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.18553\/jmcp.2020.26.10.1236","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T11:40:10Z","timestamp":1601466010000},"page":"1236-1242","source":"Crossref","is-referenced-by-count":3,"title":["The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis"],"prefix":"10.18553","volume":"26","author":[{"given":"Devin","family":"Incerti","sequence":"first","affiliation":[{"name":"Precision Health Economics, Oakland, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ervant J. Maksabedian","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Tkacz","sequence":"additional","affiliation":[{"name":"IBM Watson Health, Cambridge, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen P.","family":"Jansen","sequence":"additional","affiliation":[{"name":"Precision Health Economics, Oakland, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Collier","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdi","family":"Gharaibeh","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Moore-Schiltz","sequence":"additional","affiliation":[{"name":"IBM Watson Health, Cambridge, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley S.","family":"Stolshek","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, California."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7818","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23177"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903422307"},{"key":"B3","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/s10198-007-0088-8","volume":"8","author":"Lundkvist J","year":"2008","journal-title":"Eur J Health Econ"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/art.39480"},{"issue":"1","key":"B5","first-page":"27","volume":"10","author":"Atzinger CB","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"B6","unstructured":"Remicade (infliximab). Janssen Biotech. Malvern, PA. Revised November 2013. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/103772s5359lbl.pdf. Accessed August 26, 2010."},{"key":"B7","unstructured":"Humira (adalimumab) injection for subcutaneous use. AbbVie. North Chicago, IL. Revised March 2020. Available at: http:\/\/www.rxabbott.com\/pdf\/humira.pdf. Accessed August 22, 2019."},{"key":"B8","unstructured":"Actemra (tocilizumab) injection, for intravenous or subcutaneous use. Genentech. South San Francisco, CA. Revised May 2020. Available at: http:\/\/www.gene.com\/download\/pdf\/actemra_prescribing.pdf. Accessed August 22, 2019."},{"issue":"5","key":"B9","first-page":"737","volume":"33","author":"Moots RJ","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/art.23374"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.10.013"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1307205"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.25.1.080"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/acprof:oso\/9780190492939.001.0001"},{"issue":"6","key":"B16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40273-018-00765-2","volume":"37","author":"Incerti D","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3253-x"},{"issue":"1","key":"B18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/keg451","volume":"43","author":"Brennan A","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006560"},{"issue":"35","key":"B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20350","volume":"20","author":"Stevenson M","year":"2016","journal-title":"Health Technol Assess"},{"issue":"7","key":"B21","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3899\/jrheum.160941","volume":"44","author":"Stevenson MD","year":"2017","journal-title":"J Rheumatol"},{"key":"B22","doi-asserted-by":"crossref","first-page":"iv26","DOI":"10.1093\/rheumatology\/ker243","volume":"50","author":"Tosh J","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"B24","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/rheumatology\/kes400","volume":"52","author":"Hern\u00e1ndez Alava M","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"B25","unstructured":"Tice J, Kumar V, Chapman R, et al. Janus kinase inhibitors and biosimilars for rheumatoid arthritis. Institute for Clinical and Economic Review, January 9, 2020. Available at: https:\/\/icer-review.org\/wp-content\/uploads\/2019\/03\/ICER_RA_Final_Evidence_Report_and_Meeting_Summary_010820.pdf. Accessed August 26, 2020."},{"issue":"1","key":"B26","first-page":"26","volume":"29","author":"Moots RJ","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"B28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/rheumatology\/kel326","volume":"46","author":"Ariza-Ariza R","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"B29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1517\/13543784.2016.1126247","volume":"25","author":"Berns M","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"B30","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2006.065995","volume":"66","author":"Rahman MU","year":"2007","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T11:40:40Z","timestamp":1601466040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2020.26.10.1236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.18553\/jmcp.2020.26.10.1236"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2020.26.10.1236","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}